Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-01

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

NCT03357822

Chronic Hepatitis B

UNKNOWN PHASE4

Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary Care

NCT04904900

Chronic Hep B

RECRUITING

Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

NCT04896255

Chronic Hepatitis b

RECRUITING

A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B

NCT06041022

Hepatitis B, Chronic

UNKNOWN

Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection

NCT01480492

HBeAg Positive Chronic Hepatitis B Infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epstein-Barr virus (EBV) is an oncogenic virus implicated in the pathogenesis of a variety of human hematological malignancies such as lymphomas, hemophagocytic lymphohistiocytosis and chronic active EBV disease. While chronic latent EBV infection（especially carriers with persistent high load of EBV-DNA copy number）is the gray zone between the primary infection and the hematological malignancies, which is rarely concerned. Previous work has prompted the heterogeneities of EBV infection, such as racial heterogeneity, viral load heterogeneity and heterogeneity of infected target cells. It is of great significance to prospectively track the transforming process and elucidate the association of chronic EBV infection and hemophagocytic lymphohistiocytosis. Healthy subjects who was found to have high EBV-DNA load （\>1×103 copies/ml）in peripheral blood during the physical examination were enrolled and followed up by telephone or face-to-face interview periodically. The primary outcome is hematological malignancies including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma,EBV-associated hemophagocytic lymphohistiocytosis and Chronic active Epstein-Barr virus infection (CAEBV). The Exploratory purpose of this study is to investigate of genetic mechanisms of immune escape and tumorigenesis of EBV infection. Subgroup analysis will performed in subjects with mild high load (\>1×103 copies/ml and \<1×104 copies/ml) and severe high load (\>1×104 copies/ml) of EBV-DNA copies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

EBV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

peripheral EBV-DNA load

subjects with high load (\>1×103 copies/ml）of EBV-DNA copies in peripheral blood.

peripheral EBV-DNA load

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

peripheral EBV-DNA load

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. immunocompetent subjects who was found to have high EBV-DNA load （\>1×103 copies/ml）in peripheral blood during the physical examination
2. Willing to be followed up by telephone or face-to-face interview

Exclusion Criteria

1. Subjects with defined immunodeficiency
2. Subjects who have taken or are going to take immunosuppressive drugs.
3. Subjects Diagnosed a validated hematopathy
4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year.
5. psychological illness which does not allow subjects to understand the study and participate following his own free will
6. Pregnant woman
7. no written informed consent

Eligible Sex

ALL

Accepts Healthy Volunteers

No